We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Expands Digital Healthcare Platform via New Care Offerings
Read MoreHide Full Article
Key Takeaways
HIMS rolled out Labs and new menopause, perimenopause and testosterone treatments to widen care options.
Hims & Hers added GRAIL multi-cancer testing and bought YourBio Health for advanced blood sampling technology.
HIMS expanded via ZAVA, Livewell and Eucalyptus deals, then teamed with Novo Nordisk on GLP-1 access.
Hims & Hers Health, Inc. (HIMS - Free Report) has evolved into one of the leading consumer-focused digital healthcare platforms, using technology, telehealth infrastructure and personalized care models to reshape how patients access treatment. The company’s platform integrates telehealth consultations, electronic medical records, digital prescriptions, cloud pharmacy fulfillment and clinical support into a single ecosystem designed to make healthcare more accessible and personalized. As HIMS expands beyond traditional telehealth categories like sexual health and dermatology, it is increasingly positioning itself as a broader digital health platform supporting long-term, data-driven care across multiple specialties.
That strategy accelerated over the past year through product launches and international expansion. Hims & Hers introduced Labs, a proactive testing platform offering biomarker analysis and personalized action plans, while also launching menopause, perimenopause and testosterone treatment categories aimed at expanding preventative care. HIMS further strengthened its ecosystem through multi-cancer early detection testing in partnership with GRAIL and through acquisitions such as YourBio Health, which adds advanced blood-sampling technology to the platform.
At the same time, Hims & Hers expanded its international footprint through acquisitions, including ZAVA in Europe, Livewell in Canada and Eucalyptus across Australia, the U.K., Germany, Japan and Canada. More recently, HIMS announced a strategic collaboration with Novo Nordisk to broaden access to FDA-approved GLP-1 treatments, reinforcing its ambition to become a global platform for personalized, technology-enabled healthcare.
DOCS and AMWL Expanding Digital Healthcare Platforms
Doximity, Inc. (DOCS - Free Report) continues to strengthen its position as a leading digital healthcare platform focused on physician productivity and clinical connectivity. Doximity’s platform combines telehealth, secure messaging, digital fax, AI-powered workflow tools and medical collaboration features into an integrated ecosystem used by more than 85% of U.S. physicians. Doximity has expanded its AI offerings through the acquisition of Pathway Medical, adding evidence-based clinical reference tools to its growing AI suite. The company also reported strong adoption of its AI, telehealth and workflow products, reinforcing its role in modern healthcare delivery.
American Well Corporation (AMWL - Free Report) , popularly known as Amwell, continues to position itself as a comprehensive digital healthcare platform enabling hybrid care across virtual, automated and in-person settings. Amwell’s cloud-based platform supports health systems, payers and government clients through virtual visits, digital care programs and integrated clinical infrastructure. Amwell has secured an extension of its Military Health System Digital First contract, allowing it to continue powering virtual care delivery for nearly 9.6 million military beneficiaries globally. The company is also expanding its focus on AI-enabled care coordination and unified digital workflows, strengthening its role in technology-enabled healthcare transformation.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 13% year to date compared with the industry’s decline of 20.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 2.2X is lower than the industry’s average of 3.4X and its five-year median of 2.6X. It has a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a flat performance compared with 2025.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Expands Digital Healthcare Platform via New Care Offerings
Key Takeaways
Hims & Hers Health, Inc. (HIMS - Free Report) has evolved into one of the leading consumer-focused digital healthcare platforms, using technology, telehealth infrastructure and personalized care models to reshape how patients access treatment. The company’s platform integrates telehealth consultations, electronic medical records, digital prescriptions, cloud pharmacy fulfillment and clinical support into a single ecosystem designed to make healthcare more accessible and personalized. As HIMS expands beyond traditional telehealth categories like sexual health and dermatology, it is increasingly positioning itself as a broader digital health platform supporting long-term, data-driven care across multiple specialties.
That strategy accelerated over the past year through product launches and international expansion. Hims & Hers introduced Labs, a proactive testing platform offering biomarker analysis and personalized action plans, while also launching menopause, perimenopause and testosterone treatment categories aimed at expanding preventative care. HIMS further strengthened its ecosystem through multi-cancer early detection testing in partnership with GRAIL and through acquisitions such as YourBio Health, which adds advanced blood-sampling technology to the platform.
At the same time, Hims & Hers expanded its international footprint through acquisitions, including ZAVA in Europe, Livewell in Canada and Eucalyptus across Australia, the U.K., Germany, Japan and Canada. More recently, HIMS announced a strategic collaboration with Novo Nordisk to broaden access to FDA-approved GLP-1 treatments, reinforcing its ambition to become a global platform for personalized, technology-enabled healthcare.
Hims & Hers is scheduled to report first-quarter 2026 results on May 11, after the closing bell.
DOCS and AMWL Expanding Digital Healthcare Platforms
Doximity, Inc. (DOCS - Free Report) continues to strengthen its position as a leading digital healthcare platform focused on physician productivity and clinical connectivity. Doximity’s platform combines telehealth, secure messaging, digital fax, AI-powered workflow tools and medical collaboration features into an integrated ecosystem used by more than 85% of U.S. physicians. Doximity has expanded its AI offerings through the acquisition of Pathway Medical, adding evidence-based clinical reference tools to its growing AI suite. The company also reported strong adoption of its AI, telehealth and workflow products, reinforcing its role in modern healthcare delivery.
American Well Corporation (AMWL - Free Report) , popularly known as Amwell, continues to position itself as a comprehensive digital healthcare platform enabling hybrid care across virtual, automated and in-person settings. Amwell’s cloud-based platform supports health systems, payers and government clients through virtual visits, digital care programs and integrated clinical infrastructure. Amwell has secured an extension of its Military Health System Digital First contract, allowing it to continue powering virtual care delivery for nearly 9.6 million military beneficiaries globally. The company is also expanding its focus on AI-enabled care coordination and unified digital workflows, strengthening its role in technology-enabled healthcare transformation.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 13% year to date compared with the industry’s decline of 20.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 2.2X is lower than the industry’s average of 3.4X and its five-year median of 2.6X. It has a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a flat performance compared with 2025.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.